Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Catheter Precision, Inc. on November 17, 2025. The report addresses the termination of a material definitive agreement regarding the company's equity financing program.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial data disclosed relates to the equity offering program:
- ATM Program Cap: $4.3 million aggregate offering price.
- Shares Sold Prior to Termination: Approximately $4.0 million.
- Termination Penalties: None.
Material Changes
The primary material change is the termination of the At-Market-Offering Agreement (ATM Agreement) dated May 19, 2025, with Ladenburg Thalmann & Co. Inc. The termination is effective as of November 24, 2025. The company has substantially utilized the program, selling approximately $4.0 million of the authorized $4.3 million prior to termination.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the cessation of the ATM Program. The company confirmed it is not subject to any termination penalties associated with ending the agreement.
Investor Verification Checklist
- Verify the exact effective date of the ATM termination (November 24, 2025).
- Confirm the total proceeds raised under the ATM Program ($4.0 million) against the company's most recent 10-Q or 10-K.
- Assess the company's current liquidity position given the closure of this equity financing channel.
- Review the company's capitalization table to understand the dilution impact of the $4.0 million raised.